Liver pathology of idiopathic portal hypertension. Comparison with non‐cirrhotic portal fibrosis of India The Japan idiopathic portal hypertension study*,+

Okuda, Kunio; Nakashima, Toshiro; Okudaira, Masahiko; Kage, Masayoshi; Aida, Yoshifumi; Omata, Masao; Sugiura, Mitsuo; Kameda, Haruo; Inokuchi, Kiyoshi; Bhusnurmath, S. R.; Aikat, B. A.

doi:10.1111/j.1600-0676.1982.tb00195.x

Cited by 120 publications

(44 citation statements)

References 20 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1) [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]. Among these lesions, HCA is a benign neoplastic lesion [1,2], and the large regenerative nodule (LRN) is a large nodule observed in liver cirrhosis [10].…”

Section: Conventional Classification and Diagnostic Criteria For Benimentioning

confidence: 99%

See 1 more Smart Citation

Pathological Diagnosis of Benign Hepatocellular Nodular Lesions Based on the New World Health Organization Classification

Kondo¹,

Fukusato²,

Kudo³

2014

Oncology

View full text Add to dashboard Cite

There are various types of benign hepatocellular nodular lesions, and their diagnostic criteria were formulated in detail. However, in 2010, the new World Health Organization (WHO) classification introduced immunohistochemical diagnostic criteria for hepatocellular adenoma (HCA) reflecting molecular pathological properties, and HCA was classified into 4 subtypes. These criteria were useful for its differential diagnosis from focal nodular hyperplasia (FNH). They were also useful for the diagnosis of HCA, its subtyping, and differentiation from FNH in Japan. However, the new WHO classification is based on principles that differ from those of conventional definitions of disease concepts and methods for the differential diagnosis. Therefore, it has caused disagreements in the diagnosis in some cases. Based on this background, we present a new perspective on the diagnosis of benign hepatocellular nodular lesions.

show abstract

Section: Conventional Classification and Diagnostic Criteria For Benimentioning

confidence: 99%

“…Detailed disease concepts, definitions and methods for the differential diagnosis have been developed for various types of benign hepatocellular nodular lesions [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]. They have been applied effectively so far.…”

Section: Introductionmentioning

confidence: 99%

Pathological Diagnosis of Benign Hepatocellular Nodular Lesions Based on the New World Health Organization Classification

Kondo¹,

Fukusato²,

Kudo³

2014

Oncology

View full text Add to dashboard Cite

show abstract

“…Various terminologies have been used in an attempt to define and characterize NCIPH-idiopathic portal hypertension, [4][5][6] non-cirrhotic portal fibrosis, 7,8 nodular regenerative hyperplasia (NRH), 9 incomplete septal cirrhosis, 10 partial nodular transformation of the liver, benign intrahepatic portal hypertension and hepatoportal sclerosis. 11,12 Although their description differs in detail it is increasingly thought that they represent variations in appearance of a single pathological entity.…”

Section: Nomenclaturementioning

confidence: 99%

Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)—Newer Insights into Pathogenesis and Emerging Newer Treatment Options

Goel

Elias

Eapen

et al. 2014

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Chronic microangiopathy of portal venules results in idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH). Recent data suggest a role for vasoactive factors of portal venous origin in the pathogenesis of this 'pure' vasculopathy of the liver. Enteropathies (often silent), are an important 'driver' of this disease. NCIPH is under-recognized and often mis-labeled as cryptogenic cirrhosis. Liver biopsy is needed to prove the diagnosis of NCIPH. In these patients, with advancing disease and increased porto-systemic shunting, the portal venous vasoactive factors bypass the liver filter and contribute to the development of pulmonary vascular endothelial disorders-porto-pulmonary hypertension and hepato-pulmonary syndrome as well as mesangiocapillary glomerulonephritis. Prognosis in NCIPH patients is determined by presence, recognition and management of associated disorders. With better understanding of the pathogenesis of NCIPH, newer treatment options are being explored. Imbalance in ADAMTS 13 (a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13): vWF (von-Willebrand factor) ratio is documented in NCIPH patients and may have a pathogenic role. Therapeutic interventions to correct this imbalance may prove to be important in the management of NCIPH. ( J CLIN EXP HEPATOL 2014;4:247-256) T he term "portal hypertension" is used to reflect a clinical condition secondary to increased pressure in the hepatic portal circulation. Clinically, it usually presents with symptoms or signs of gastroesophageal varices, ascites, encephalopathy, splenomegaly and/or hypersplenism. Portal hypertension can be classified in terms of the anatomic location of the causal resistance to portal blood flow as pre-hepatic (e.g. portal vein thrombosis), post-hepatic (e.g. Budd-Chiari syndrome) and intrahepatic. Intrahepatic portal hypertension can be further sub-classified as pre-sinusoidal (e.g. congenital hepatic fibrosis) or sinusoidal (sinusoidal obstruction syndrome/ veno-occlusive disease). This review focuses on idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH), a cause of pre-sinusoidal intrahepatic portal hypertension.NCIPH occurs as a consequence of increased resistance to flow within intrahepatic portal vein radicles. Based on vascular corrosion cast and morphometric studies, the site of narrowing or occlusion was localized to the 3rd/4th order portal vein radicles. Boyer 1 and Wanless 2 proposed that the pruning of portal vein radicles is a consequence of thrombosis, but this view is not universally accepted. Sarin et al 3 have shown that there are two independent pressure gradients, one between intra-splenic and intrahepatic pressure and another between intrahepatic and wedged hepatic venous pressure indicating the likelihood of both presinusoidal and peri-sinusoidal resistance to blood flow. Intra-variceal pressure is representative of portal pressure. 3 NOMENCLATUREVarious terminologies have been used in an attempt to define and characterize NCIPH-idiopathic portal hypertensio...

show abstract

“…Idiopathic portal hypertension (IPH), or Banti's syndrome, is relatively frequent in several Asian countries, including Japan and India, as compared with the prevalence in the United States and Europe (1)(2)(3). Because IPH is characterized by prominent portal fibrosis despite no fibrotic changes in the liver parenchyma, this disease also has been referred to as hepatoportal sclerosis (4) or noncirrhotic portal fibrosis (2).…”

Section: Introductionmentioning

confidence: 99%

Expression of Connective Tissue Growth Factor in the Human Liver with Idiopathic Portal Hypertension

Morikawa

Tamori

Nishiguchi

et al. 2007

Mol Med

View full text Add to dashboard Cite

Liver pathology of idiopathic portal hypertension. Comparison with non‐cirrhotic portal fibrosis of India The Japan idiopathic portal hypertension study*,+

Cited by 120 publications

References 20 publications

Pathological Diagnosis of Benign Hepatocellular Nodular Lesions Based on the New World Health Organization Classification

Pathological Diagnosis of Benign Hepatocellular Nodular Lesions Based on the New World Health Organization Classification

Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)—Newer Insights into Pathogenesis and Emerging Newer Treatment Options

Expression of Connective Tissue Growth Factor in the Human Liver with Idiopathic Portal Hypertension

Contact Info

Product

Resources

About